Clinical Edge Journal Scan

Autoimmune Diseases Increase PsA Risk


 

Key clinical point: Patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), and certain other autoimmune diseases (AID) may have an increased risk of developing psoriatic arthritis (PsA).

Major finding: The risk factors for PsA included RA (inverse variance weighting odds ratio [OR IVW] 1.11; P = .0205), SLE (OR IVW 1.04; P = .0107), AS (OR IVW 2.18; P = .000155), Crohn's disease (CD; OR IVW 1.07; P = .01), Hashimoto's thyroiditis (HT; OR IVW 1.23; P = .00143), and vitiligo (OR IVW 1.27; P = .0000267) . However, PsA did not increase the risk for these AID.

Study details: This bidirectional two-sample Mendelian randomization study used genome-wide association data for PsA (3186 cases and 240,862 control individuals and an additional 5065 cases and 21,286 control individuals), psoriasis, and AID.

Disclosures: This study was supported by two research projects from China. The authors declared no conflicts of interest.

Source: Duan K, Wang J, Chen S, et al. Causal associations between both psoriasis and psoriatic arthritis and multiple autoimmune diseases: A bidirectional two-sample Mendelian randomization study. Front. Immunol. 2024;15:1422626 (Jul 24). Doi: 10.3389/fimmu.2024.1422626 Source

Recommended Reading

Study Finds Differences in Side Effect Profiles With Two Oral Psoriasis Therapies
MDedge Rheumatology
Advantages of a Pediatric Rheumatology/Dermatology Clinic Evaluated
MDedge Rheumatology
Trends in Rheumatic Disease Pain Management Show Decline in Opioid Use
MDedge Rheumatology
US Experience With Infliximab Biosimilars Suggests Need for More Development Incentives
MDedge Rheumatology
Bimekizumab Shows Promising Outcomes in PsA, With or Without Methotrexate
MDedge Rheumatology
IL-23 and IL-12/23 Inhibitors Show Comparable Safety in Preventing PsA in Psoriasis
MDedge Rheumatology
Achieving Disease Control Linked to Better Quality of Life in PsA
MDedge Rheumatology
Sparing Effect of First-Line Targeted Therapy in PsA
MDedge Rheumatology
Bimekizumab Outperforms Ustekinumab for PsA in a Matching-Adjusted Indirect Comparison
MDedge Rheumatology
Right Hand and Right Knee Joints Most Affected in PsA
MDedge Rheumatology